Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15198506,liver/tumor uptake ratio,"The liver/tumor uptake ratio of free drug, conventional (LL), and sterically stabilized liposomes (SLL5000 and SLL2000) was found to be 20, 7.99, 1.63, and 1.23, respectively, which showed the increased accumulation of sterically stabilized liposomes in tumor compared with the free drug and conventional liposomes at 24 hours postinjection.","Preparation, characterization, and biodistribution study of technetium-99m -labeled leuprolide acetate-loaded liposomes in Ehrlich ascites tumor-bearing mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198506/),,20,14518,DB00007,Leuprolide
,15198506,liver/tumor uptake ratio,"The liver/tumor uptake ratio of free drug, conventional (LL), and sterically stabilized liposomes (SLL5000 and SLL2000) was found to be 20, 7.99, 1.63, and 1.23, respectively, which showed the increased accumulation of sterically stabilized liposomes in tumor compared with the free drug and conventional liposomes at 24 hours postinjection.","Preparation, characterization, and biodistribution study of technetium-99m -labeled leuprolide acetate-loaded liposomes in Ehrlich ascites tumor-bearing mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198506/),,7.99,14519,DB00007,Leuprolide
,15198506,liver/tumor uptake ratio,"The liver/tumor uptake ratio of free drug, conventional (LL), and sterically stabilized liposomes (SLL5000 and SLL2000) was found to be 20, 7.99, 1.63, and 1.23, respectively, which showed the increased accumulation of sterically stabilized liposomes in tumor compared with the free drug and conventional liposomes at 24 hours postinjection.","Preparation, characterization, and biodistribution study of technetium-99m -labeled leuprolide acetate-loaded liposomes in Ehrlich ascites tumor-bearing mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198506/),,1.63,14520,DB00007,Leuprolide
,15198506,liver/tumor uptake ratio,"The liver/tumor uptake ratio of free drug, conventional (LL), and sterically stabilized liposomes (SLL5000 and SLL2000) was found to be 20, 7.99, 1.63, and 1.23, respectively, which showed the increased accumulation of sterically stabilized liposomes in tumor compared with the free drug and conventional liposomes at 24 hours postinjection.","Preparation, characterization, and biodistribution study of technetium-99m -labeled leuprolide acetate-loaded liposomes in Ehrlich ascites tumor-bearing mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198506/),,1.23,14521,DB00007,Leuprolide
,30653693,Relative recoveries,"Relative recoveries of leuprolide and triptorelin were found to be 80.3 and 75.5%, respectively.",Quantification of controlled release leuprolide and triptorelin in rabbit plasma using electromembrane extraction coupled with HPLC-UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30653693/),%,80.3,19485,DB00007,Leuprolide
,30653693,Relative recoveries,"Relative recoveries of leuprolide and triptorelin were found to be 80.3 and 75.5%, respectively.",Quantification of controlled release leuprolide and triptorelin in rabbit plasma using electromembrane extraction coupled with HPLC-UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30653693/),%,75.5,19486,DB00007,Leuprolide
,30653693,Limits,"Limits of quantification and detection for both peptides were found to be 0.5 and 0.15 ng/mL, respectively.",Quantification of controlled release leuprolide and triptorelin in rabbit plasma using electromembrane extraction coupled with HPLC-UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30653693/),[ng] / [ml],0.5,19487,DB00007,Leuprolide
,22421322,zeta potential,"The thiolated (chitosan-TGA) NPs had a mean size of 252 ± 82 nm, a zeta potential of +10.9 ± 4 mV, and payload of leuprolide was 12 ± 2.8.",Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22421322/),m,10.9,32560,DB00007,Leuprolide
,22421322,relative nasal bioavailability,The relative nasal bioavailability (versus s.c. injection) of leuprolide thiolated NPs calculated on the basis of AUC((0-6)) was about 19.6% as compared to leuprolide solution 2.8%.,Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22421322/),%,19.6,32561,DB00007,Leuprolide
,22421322,relative nasal bioavailability,The relative nasal bioavailability (versus s.c. injection) of leuprolide thiolated NPs calculated on the basis of AUC((0-6)) was about 19.6% as compared to leuprolide solution 2.8%.,Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22421322/),%,2.8,32562,DB00007,Leuprolide
,29434672,Cmax,"The initial surge of LA was higher for IM-LA than SC-LA (Cmax 27 ± 4.9 versus 19 ± 8.0 ng/ml, respectively), with a shorter tmax (1.0 ± 0.4 versus 2.1 ± 0.8 h).",Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29434672/),[ng] / [ml],27,37909,DB00007,Leuprolide
,29434672,Cmax,"The initial surge of LA was higher for IM-LA than SC-LA (Cmax 27 ± 4.9 versus 19 ± 8.0 ng/ml, respectively), with a shorter tmax (1.0 ± 0.4 versus 2.1 ± 0.8 h).",Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29434672/),[ng] / [ml],19,37910,DB00007,Leuprolide
,29434672,tmax,"The initial surge of LA was higher for IM-LA than SC-LA (Cmax 27 ± 4.9 versus 19 ± 8.0 ng/ml, respectively), with a shorter tmax (1.0 ± 0.4 versus 2.1 ± 0.8 h).",Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29434672/),h,1.0,37911,DB00007,Leuprolide
,29434672,tmax,"The initial surge of LA was higher for IM-LA than SC-LA (Cmax 27 ± 4.9 versus 19 ± 8.0 ng/ml, respectively), with a shorter tmax (1.0 ± 0.4 versus 2.1 ± 0.8 h).",Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29434672/),h,2.1,37912,DB00007,Leuprolide
,10425368,permeability coefficients,"In vitro permeability of leuprolide in the rabbit GI tract was performed using a side-by-side diffusion apparatus and the permeability coefficients in the jejunum, ileum and colon were 0.27x10(-7), 2.96x10(-7) and 7.85x10(-7)cm/s, respectively.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),[cm] / [s],0.27x10(-7),45316,DB00007,Leuprolide
,10425368,permeability coefficients,"In vitro permeability of leuprolide in the rabbit GI tract was performed using a side-by-side diffusion apparatus and the permeability coefficients in the jejunum, ileum and colon were 0.27x10(-7), 2.96x10(-7) and 7.85x10(-7)cm/s, respectively.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),[cm] / [s],2.96x10(-7),45317,DB00007,Leuprolide
,10425368,permeability coefficients,"In vitro permeability of leuprolide in the rabbit GI tract was performed using a side-by-side diffusion apparatus and the permeability coefficients in the jejunum, ileum and colon were 0.27x10(-7), 2.96x10(-7) and 7.85x10(-7)cm/s, respectively.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),[cm] / [s],7.85x10(-7),45318,DB00007,Leuprolide
,10425368,bioavailabilities,"Using an intestine loop model in anesthetized rats, bioavailabilities of leuprolide in the jejunum, ileum and colon were 1.28, 5.62 and 9.59%, respectively.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,1.28,45319,DB00007,Leuprolide
,10425368,bioavailabilities,"Using an intestine loop model in anesthetized rats, bioavailabilities of leuprolide in the jejunum, ileum and colon were 1.28, 5.62 and 9.59%, respectively.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,5.62,45320,DB00007,Leuprolide
,10425368,bioavailabilities,"Using an intestine loop model in anesthetized rats, bioavailabilities of leuprolide in the jejunum, ileum and colon were 1.28, 5.62 and 9.59%, respectively.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,9.59,45321,DB00007,Leuprolide
,10425368,Drug recovery,"Drug recovery from the loop 5 h after dosing was 10.7% in jejunum, 24.5% in ileum and 40.7% in colon.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,10.7,45322,DB00007,Leuprolide
,10425368,Drug recovery,"Drug recovery from the loop 5 h after dosing was 10.7% in jejunum, 24.5% in ileum and 40.7% in colon.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,24.5,45323,DB00007,Leuprolide
,10425368,Drug recovery,"Drug recovery from the loop 5 h after dosing was 10.7% in jejunum, 24.5% in ileum and 40.7% in colon.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,40.7,45324,DB00007,Leuprolide
less,10425368,bioavailability,Additional in vivo studies using conscious rats showed that the bioavailability of leuprolide was less than 1% for both ileal and colonic administration.,Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,1,45325,DB00007,Leuprolide
,20435244,AUC(0-t),"Values for AUC(0-t) calculated from day 0 to day 28, days 28 to 56, and days 56 to 84 were 25,976.5 (7892.0), 30,685.5 (9348.4), and 31,030.9 (10,745.0) pg/mL per day, respectively.","Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435244/),[pg] / [d·ml],"25,976.5",48323,DB00007,Leuprolide
,20435244,AUC(0-t),"Values for AUC(0-t) calculated from day 0 to day 28, days 28 to 56, and days 56 to 84 were 25,976.5 (7892.0), 30,685.5 (9348.4), and 31,030.9 (10,745.0) pg/mL per day, respectively.","Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435244/),[pg] / [d·ml],"30,685.5",48324,DB00007,Leuprolide
,20435244,AUC(0-t),"Values for AUC(0-t) calculated from day 0 to day 28, days 28 to 56, and days 56 to 84 were 25,976.5 (7892.0), 30,685.5 (9348.4), and 31,030.9 (10,745.0) pg/mL per day, respectively.","Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435244/),[pg] / [d·ml],"31,030.9",48325,DB00007,Leuprolide
,2513176,area under the serum concentration-time curve from zero to 35 days (AUC0-35 days),A significant dose-dependent increase in the area under the serum concentration-time curve from zero to 35 days (AUC0-35 days) from 541.7 to 1653.9 ng/ml.h was also noted (p less than 0.01).,"Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2513176/),[ng] / [h·ml],541.7 to 1653.9,60280,DB00007,Leuprolide
<,24756362,peak-stimulated LH concentrations,The probability of LH suppression (peak-stimulated LH concentrations <4 mIU/mL) exposure-response relationship was modelled using repeated measures logistic regression.,Pharmacokinetic and exposure-response analyses of leuprolide following administration of leuprolide acetate 3-month depot formulations to children with central precocious puberty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24756362/),[miu] / [ml],4,84851,DB00007,Leuprolide
,21277965,% recoveries,"LA was stable in the patch, % recoveries for 3 months were 102.2±1.9-95.3±1.9%.",Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),%,102.2,95351,DB00007,Leuprolide
,21277965,% recoveries,"LA was stable in the patch, % recoveries for 3 months were 102.2±1.9-95.3±1.9%.",Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),%,95.3,95352,DB00007,Leuprolide
,21277965,C(max),"Plasma LA concentrations increased immediately after administration, and reached to the maximum level at 15 min, where C(max) were 6.0±0.7 and 16.4±0.9 μg/ml, respectively.",Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),[μg] / [ml],6.0,95353,DB00007,Leuprolide
,21277965,C(max),"Plasma LA concentrations increased immediately after administration, and reached to the maximum level at 15 min, where C(max) were 6.0±0.7 and 16.4±0.9 μg/ml, respectively.",Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),[μg] / [ml],16.4,95354,DB00007,Leuprolide
,21277965,AUC,The AUC were 5.8±0.8 and 14.5±0.4 μg h/ml and BA were 33.8±4.3% and 31.7±0.8%.,Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),[h·μg] / [ml],5.8,95355,DB00007,Leuprolide
,21277965,AUC,The AUC were 5.8±0.8 and 14.5±0.4 μg h/ml and BA were 33.8±4.3% and 31.7±0.8%.,Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),[h·μg] / [ml],14.5,95356,DB00007,Leuprolide
,21277965,BA,The AUC were 5.8±0.8 and 14.5±0.4 μg h/ml and BA were 33.8±4.3% and 31.7±0.8%.,Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),%,33.8,95357,DB00007,Leuprolide
,21277965,BA,The AUC were 5.8±0.8 and 14.5±0.4 μg h/ml and BA were 33.8±4.3% and 31.7±0.8%.,Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),%,31.7,95358,DB00007,Leuprolide
,21277965,Relative BA,Relative BA of LA from dissolving microneedles against s.c. solution was 105.6±13.5%.,Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),%,105.6,95359,DB00007,Leuprolide
,21277965,half-life,The degradation rate of LA in the rat skin tissue homogenate was very fast where the half-life was 16.3±5.7 min.,Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),min,16.3,95360,DB00007,Leuprolide
,25583642,circulation half-life,"Compared to the soluble peptide, the leuprolide-entrapped CCL-PMs showed a prolonged circulation half-life (14.4h) following a single intravenous injection in healthy rats and the released leuprolide was detected in blood for 3days.",A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25583642/),h,14.4,97545,DB00007,Leuprolide
,25460544,Bioavailability,Bioavailability of leuprolide following pulmonary administration was 75% higher compared to subcutaneously administered leuprolide.,Effect of protease inhibitors on pulmonary bioavailability of therapeutic proteins and peptides in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25460544/),%,75,100120,DB00007,Leuprolide
,6425491,biological half-lives,"Although leuprolide disappeared rapidly from the serum after intravenous administration (the biological half-lives were 8.4 min in the alpha-phase and 33.2 min in the beta-phase), long-lasting serum levels were observed when the analogue was administered vaginally.",Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425491/),min,8.4,118883,DB00007,Leuprolide
,6425491,biological half-lives,"Although leuprolide disappeared rapidly from the serum after intravenous administration (the biological half-lives were 8.4 min in the alpha-phase and 33.2 min in the beta-phase), long-lasting serum levels were observed when the analogue was administered vaginally.",Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425491/),min,33.2,118884,DB00007,Leuprolide
,6425491,absolute bioavailability,"The absolute bioavailability, estimated by the AUC of serum leuprolide levels, was 25.8% over 6 h and 38.0% over 12 h in the 5% citric acid solution (pH 3.5).",Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425491/),%,25.8,118885,DB00007,Leuprolide
,6425491,absolute bioavailability,"The absolute bioavailability, estimated by the AUC of serum leuprolide levels, was 25.8% over 6 h and 38.0% over 12 h in the 5% citric acid solution (pH 3.5).",Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425491/),%,38.0,118886,DB00007,Leuprolide
,31906491,maximum plasma concentration,"The maximum plasma concentration and the area under the plasma concentration-time curve from zero to infinity from the predicted PK profile were 4.01 ng/mL and 52.52 h·ng/mL, respectively, and from the observed PK profile were 4.14 ng/mL and 56.95 h·ng/mL, respectively.","Development of Level A In Vitro-Vivo Correlation for Electrosprayed Microspheres Containing Leuprolide: Physicochemical, Pharmacokinetic, and Pharmacodynamic Evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31906491/),[ng] / [ml],4.01,130469,DB00007,Leuprolide
,31906491,maximum plasma concentration,"The maximum plasma concentration and the area under the plasma concentration-time curve from zero to infinity from the predicted PK profile were 4.01 ng/mL and 52.52 h·ng/mL, respectively, and from the observed PK profile were 4.14 ng/mL and 56.95 h·ng/mL, respectively.","Development of Level A In Vitro-Vivo Correlation for Electrosprayed Microspheres Containing Leuprolide: Physicochemical, Pharmacokinetic, and Pharmacodynamic Evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31906491/),[ng] / [ml],4.14,130470,DB00007,Leuprolide
,31906491,area under the plasma concentration-time curve from zero to infinity,"The maximum plasma concentration and the area under the plasma concentration-time curve from zero to infinity from the predicted PK profile were 4.01 ng/mL and 52.52 h·ng/mL, respectively, and from the observed PK profile were 4.14 ng/mL and 56.95 h·ng/mL, respectively.","Development of Level A In Vitro-Vivo Correlation for Electrosprayed Microspheres Containing Leuprolide: Physicochemical, Pharmacokinetic, and Pharmacodynamic Evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31906491/),[h·ng] / [ml],52.52,130471,DB00007,Leuprolide
,31906491,area under the plasma concentration-time curve from zero to infinity,"The maximum plasma concentration and the area under the plasma concentration-time curve from zero to infinity from the predicted PK profile were 4.01 ng/mL and 52.52 h·ng/mL, respectively, and from the observed PK profile were 4.14 ng/mL and 56.95 h·ng/mL, respectively.","Development of Level A In Vitro-Vivo Correlation for Electrosprayed Microspheres Containing Leuprolide: Physicochemical, Pharmacokinetic, and Pharmacodynamic Evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31906491/),[h·ng] / [ml],56.95,130472,DB00007,Leuprolide
,12187267,breakthrough response,A patient with a breakthrough response after testosterone suppression on day 49 (112 ng./dl.) regained suppression (27 ng./dl.) 14 days after the second injection (day 98).,A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12187267/),ng,112,142437,DB00007,Leuprolide
,8069567,Absorption,"Absorption was low, approximately 0.01% and 0.08% by oral (PO) and ID administration respectively, compared with intravenous (i.v.) controls.",Effect of formulation adjuvants on gastrointestinal absorption of leuprolide acetate. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8069567/),%,0.01,150596,DB00007,Leuprolide
,8069567,Absorption,"Absorption was low, approximately 0.01% and 0.08% by oral (PO) and ID administration respectively, compared with intravenous (i.v.) controls.",Effect of formulation adjuvants on gastrointestinal absorption of leuprolide acetate. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8069567/),%,0.08,150597,DB00007,Leuprolide
,8069567,bioavailabilities,"An aqueous formulation and a water in oil emulsion of a lipophilic salt, a decane sulfonic acid derivative of [D-Leu6-desGly10]LH-RH ethylamide gave ID bioavailabilities of approximately 0.2% and 1%, respectively.",Effect of formulation adjuvants on gastrointestinal absorption of leuprolide acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8069567/),%,0.2,150598,DB00007,Leuprolide
,8069567,bioavailabilities,"An aqueous formulation and a water in oil emulsion of a lipophilic salt, a decane sulfonic acid derivative of [D-Leu6-desGly10]LH-RH ethylamide gave ID bioavailabilities of approximately 0.2% and 1%, respectively.",Effect of formulation adjuvants on gastrointestinal absorption of leuprolide acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8069567/),%,1,150599,DB00007,Leuprolide
,8069567,Absolute bioavailability,Absolute bioavailability of the drug in typical emulsion systems ranged from approximately 3 to 10% and represent an improvement of about 100 fold in gastrointestinal bioavailability of this peptide.,Effect of formulation adjuvants on gastrointestinal absorption of leuprolide acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8069567/),%,3 to 10,150600,DB00007,Leuprolide
,10053199,absolute bioavailability,The estimate of absolute bioavailability of leuprolide was 46.7% in dogs compared with 2.7% in monkeys at an equivalent dose of 0.45 mg/kg.,Sublingual absorption of leuprolide: comparison between human and animal models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10053199/),%,46.7,153915,DB00007,Leuprolide
,10053199,absolute bioavailability,The estimate of absolute bioavailability of leuprolide was 46.7% in dogs compared with 2.7% in monkeys at an equivalent dose of 0.45 mg/kg.,Sublingual absorption of leuprolide: comparison between human and animal models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10053199/),%,2.7,153916,DB00007,Leuprolide
,10053199,Absolute bioavailabilities,"Absolute bioavailabilities in humans were 2.0, 2.3 and 2.4% at doses of 1.125, 2.25 and 4.5 mg, respectively.",Sublingual absorption of leuprolide: comparison between human and animal models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10053199/),%,2.0,153917,DB00007,Leuprolide
,10053199,Absolute bioavailabilities,"Absolute bioavailabilities in humans were 2.0, 2.3 and 2.4% at doses of 1.125, 2.25 and 4.5 mg, respectively.",Sublingual absorption of leuprolide: comparison between human and animal models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10053199/),%,2.3,153918,DB00007,Leuprolide
,10053199,Absolute bioavailabilities,"Absolute bioavailabilities in humans were 2.0, 2.3 and 2.4% at doses of 1.125, 2.25 and 4.5 mg, respectively.",Sublingual absorption of leuprolide: comparison between human and animal models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10053199/),%,2.4,153919,DB00007,Leuprolide
,12501882,maximal concentration,"LA had a mean (SD) maximal concentration of 26.3 (12.6) ng/mL at 4.66 (1.44) hours and was detected for a mean of 37 days (range, 28-49 days).","A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501882/),[ng] / [ml],26.3,157399,DB00007,Leuprolide
,2108885,peak concentration,"Serum leuprorelin concentrations increased immediately after injection, reaching a peak concentration (range 13.1-54.5 ng/ml), which was directly proportional to dose, within 3 h.",Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2108885/),[ng] / [ml],13.1-54.5,159487,DB00007,Leuprolide
,3083092,beta half-life,The mean beta half-life after the intravenous dosings was 2.9 h and after the subcutaneous dosings was 3.6 h.,Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),h,2.9,161103,DB00007,Leuprolide
,3083092,beta half-life,The mean beta half-life after the intravenous dosings was 2.9 h and after the subcutaneous dosings was 3.6 h.,Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),h,3.6,161104,DB00007,Leuprolide
,3083092,mean residence time,"The mean residence time following the intravenous dosings averaged 3.1 h and following the subcutaneous dosings averaged 4.3 h, indicating an average mean residence time at the subcutaneous injection site of 1.2 h.",Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),h,3.1,161105,DB00007,Leuprolide
,3083092,mean residence time,"The mean residence time following the intravenous dosings averaged 3.1 h and following the subcutaneous dosings averaged 4.3 h, indicating an average mean residence time at the subcutaneous injection site of 1.2 h.",Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),h,4.3,161106,DB00007,Leuprolide
,3083092,mean residence time,"The mean residence time following the intravenous dosings averaged 3.1 h and following the subcutaneous dosings averaged 4.3 h, indicating an average mean residence time at the subcutaneous injection site of 1.2 h.",Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),h,1.2,161107,DB00007,Leuprolide
,3083092,volume of distribution at steady state,"The mean volume of distribution at steady state from the intravenous and subcutaneous doses were 26.5 and 37.1 L, respectively.",Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),l,26.5,161108,DB00007,Leuprolide
,3083092,volume of distribution at steady state,"The mean volume of distribution at steady state from the intravenous and subcutaneous doses were 26.5 and 37.1 L, respectively.",Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),l,37.1,161109,DB00007,Leuprolide
,25633239,AUC0-192,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),[h·iu] / [l],424.90,164547,DB00007,Leuprolide
,25633239,AUC0-192,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),[h·iu] / [l],432.75,164548,DB00007,Leuprolide
,25633239,C max,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),[iu] / [l],0.98,164549,DB00007,Leuprolide
,25633239,C max,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),[iu] / [l],0.95,164550,DB00007,Leuprolide
,25633239,T max,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),h,24.0,164551,DB00007,Leuprolide
,25633239,T max,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),h,24.0,164552,DB00007,Leuprolide
,25633239,t 1/2,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),h,43.58,164553,DB00007,Leuprolide
,25633239,t 1/2,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),h,42.58,164554,DB00007,Leuprolide
,25633239,K e,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),[1] / [h],0.0075,164555,DB00007,Leuprolide
,25633239,K e,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),[1] / [h],0.0077,164556,DB00007,Leuprolide
,25791895,absorption rate constant,"Typical population values of the absorption rate constant of the immediate and delayed processes were estimated to be 0.357 and 0.017 day(-1), respectively, with a mean transit time of 9.5 days.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),1/[day],0.357,167174,DB00007,Leuprolide
,25791895,absorption rate constant,"Typical population values of the absorption rate constant of the immediate and delayed processes were estimated to be 0.357 and 0.017 day(-1), respectively, with a mean transit time of 9.5 days.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),1/[day],0.017,167175,DB00007,Leuprolide
,25791895,mean transit time,"Typical population values of the absorption rate constant of the immediate and delayed processes were estimated to be 0.357 and 0.017 day(-1), respectively, with a mean transit time of 9.5 days.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),d,9.5,167176,DB00007,Leuprolide
,25791895,equilibrium dissociation constant,"The equilibrium dissociation constant of leuprolide and the typical leuprolide plasma concentration required to achieve a castration testosterone level of ≤0.5 ng/mL were 0.3 and 0.03 ng/mL, respectively.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),[ng] / [ml],0.3,167177,DB00007,Leuprolide
,25791895,equilibrium dissociation constant,"The equilibrium dissociation constant of leuprolide and the typical leuprolide plasma concentration required to achieve a castration testosterone level of ≤0.5 ng/mL were 0.3 and 0.03 ng/mL, respectively.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),[ng] / [ml],0.03,167178,DB00007,Leuprolide
,27824264,encapsulation efficiency,"The encapsulation efficiency and loading content of the drug in the Luphere 3M Depot were 94.7% and 9.92% (w/w), respectively.","Comparative in vitro release and clinical pharmacokinetics of leuprolide from Luphere 3M Depot, a 3-month release formulation of leuprolide acetate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27824264/),%,94.7,168743,DB00007,Leuprolide
,27824264,loading content,"The encapsulation efficiency and loading content of the drug in the Luphere 3M Depot were 94.7% and 9.92% (w/w), respectively.","Comparative in vitro release and clinical pharmacokinetics of leuprolide from Luphere 3M Depot, a 3-month release formulation of leuprolide acetate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27824264/),%,9.92,168744,DB00007,Leuprolide
,1553349,bioavailable,The s.c. injection was 94% bioavailable compared with i.v.,Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),%,94,191598,DB00007,Leuprolide
,1553349,bioavailability,"The i.n. bioavailability averaged 2.4%, with significant subject-to-subject variability.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),%,2.4,191599,DB00007,Leuprolide
,1553349,Plasma peak concentrations (Cmax),"Plasma peak concentrations (Cmax) with 1- and 3-mg dosages ranged between 0.24-1.6 and 0.10-11.0 ng/ml, respectively.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),[ng] / [ml],0.24-1.6,191600,DB00007,Leuprolide
,1553349,Plasma peak concentrations (Cmax),"Plasma peak concentrations (Cmax) with 1- and 3-mg dosages ranged between 0.24-1.6 and 0.10-11.0 ng/ml, respectively.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),[ng] / [ml],0.10-11.0,191601,DB00007,Leuprolide
,1553349,Cmax,"Mean Cmax with a 1-mg dose of solution aerosol was 0.97 ng/ml, compared with 4.4 and 11.4 ng/ml for suspension aerosols given at 1- and 2-mg bolus dosages, respectively.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),[ng] / [ml],0.97,191602,DB00007,Leuprolide
,1553349,Cmax,"Mean Cmax with a 1-mg dose of solution aerosol was 0.97 ng/ml, compared with 4.4 and 11.4 ng/ml for suspension aerosols given at 1- and 2-mg bolus dosages, respectively.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),[ng] / [ml],4.4,191603,DB00007,Leuprolide
,1553349,Cmax,"Mean Cmax with a 1-mg dose of solution aerosol was 0.97 ng/ml, compared with 4.4 and 11.4 ng/ml for suspension aerosols given at 1- and 2-mg bolus dosages, respectively.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),[ng] / [ml],11.4,191604,DB00007,Leuprolide
,1553349,bioavailability,"The mean bioavailability of the suspension aerosols (28% relative to s.c. administration) was fourfold greater than that of the solution aerosol (6.6%), suggesting that LHRH analogues may be delivered systemically via the lung as aerosol dispersions.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),%,28,191605,DB00007,Leuprolide
,1553349,bioavailability,"The mean bioavailability of the suspension aerosols (28% relative to s.c. administration) was fourfold greater than that of the solution aerosol (6.6%), suggesting that LHRH analogues may be delivered systemically via the lung as aerosol dispersions.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),%,6.6,191606,DB00007,Leuprolide
,29662027,absorption rate constant,"The absorption rate constant, the total body clearance, and the volume of distribution were estimated at 16.67 h-1, 514.46 mL/h, and 487.40 mL.",Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29662027/),1/[h],16.67,202805,DB00007,Leuprolide
,29662027,total body clearance,"The absorption rate constant, the total body clearance, and the volume of distribution were estimated at 16.67 h-1, 514.46 mL/h, and 487.40 mL.",Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29662027/),[ml] / [h],514.46,202806,DB00007,Leuprolide
,29662027,volume of distribution,"The absorption rate constant, the total body clearance, and the volume of distribution were estimated at 16.67 h-1, 514.46 mL/h, and 487.40 mL.",Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29662027/),ml,487.40,202807,DB00007,Leuprolide
,9563139,peak serum concentration (Cmax),"The 3-month depot showed a higher median peak serum concentration (Cmax) of leuprorelin at 20.8 ng/ml than the 1-month depot at 10.7 ng/ml but, conversely, this did not influence the rise in serum testosterone levels.",Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9563139/),[ng] / [ml],20.8,204441,DB00007,Leuprolide
,9563139,peak serum concentration (Cmax),"The 3-month depot showed a higher median peak serum concentration (Cmax) of leuprorelin at 20.8 ng/ml than the 1-month depot at 10.7 ng/ml but, conversely, this did not influence the rise in serum testosterone levels.",Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9563139/),[ng] / [ml],10.7,204442,DB00007,Leuprolide
,32738042,growth velocity,Mean growth velocity decreased from 8.9 cm/year at week 4 to 6.0 cm/year at week 48.,Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32738042/),[cm] / [year],8.9,223763,DB00007,Leuprolide
,32738042,growth velocity,Mean growth velocity decreased from 8.9 cm/year at week 4 to 6.0 cm/year at week 48.,Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32738042/),[cm] / [year],6.0,223764,DB00007,Leuprolide
,16406989,time to castrate suppression,Mean time to castrate suppression was 21.2 days (median 21).,A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16406989/),d,21.2,230642,DB00007,Leuprolide
,2570847,release rate,The release of the drug in rats after a single subcutaneous injection exhibited pseudo-zero-order kinetics for one month in doses ranging from 0.0135 to 1.35 mg/rat; the release rate at a dose of 1.35 mg/rat was 2.8% of dose/day; after intramuscular injection the response was similar.,"Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2570847/),%,2.8,236929,DB00007,Leuprolide
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],13.1,240897,DB00007,Leuprolide
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],20.8,240898,DB00007,Leuprolide
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],21,240899,DB00007,Leuprolide
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],.,240900,DB00007,Leuprolide
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],8,240901,DB00007,Leuprolide
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],47.4,240902,DB00007,Leuprolide
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],54.5,240903,DB00007,Leuprolide
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],53,240904,DB00007,Leuprolide
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],32 to 35,240905,DB00007,Leuprolide
,12083977,volume of distribution,"Mean volume of distribution of leuprorelin is 37L after a single subcutaneous injection of 1mg, and 36, 33 and 27L after depot administration of 3.75, 7.5 and 15mg, respectively.",Clinical pharmacokinetics of depot leuprorelin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),l,37,240906,DB00007,Leuprolide
,12083977,volume of distribution,"Mean volume of distribution of leuprorelin is 37L after a single subcutaneous injection of 1mg, and 36, 33 and 27L after depot administration of 3.75, 7.5 and 15mg, respectively.",Clinical pharmacokinetics of depot leuprorelin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),l,36,240907,DB00007,Leuprolide
,12083977,volume of distribution,"Mean volume of distribution of leuprorelin is 37L after a single subcutaneous injection of 1mg, and 36, 33 and 27L after depot administration of 3.75, 7.5 and 15mg, respectively.",Clinical pharmacokinetics of depot leuprorelin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),l,33,240908,DB00007,Leuprolide
,12083977,volume of distribution,"Mean volume of distribution of leuprorelin is 37L after a single subcutaneous injection of 1mg, and 36, 33 and 27L after depot administration of 3.75, 7.5 and 15mg, respectively.",Clinical pharmacokinetics of depot leuprorelin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),l,27,240909,DB00007,Leuprolide
,12083977,Total body clearance,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[l] / [h],9.1,240910,DB00007,Leuprolide
,12083977,Total body clearance,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),h,3.6,240911,DB00007,Leuprolide
,12083977,Total body clearance,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[l] / [h],8.3,240912,DB00007,Leuprolide
,12083977,Total body clearance,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),h,2.9,240913,DB00007,Leuprolide
,12083977,elimination half-life,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),h,3.6,240914,DB00007,Leuprolide
,12083977,elimination half-life,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[l] / [h],8.3,240915,DB00007,Leuprolide
,12083977,elimination half-life,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),h,2.9,240916,DB00007,Leuprolide
,12083977,C(max),"A 3-month depot PLA formulation of leuprorelin acetate 11.25mg ensures a C(max) of around 20 microg/L at 3 hours after subcutaneous injection, and continuous drug concentrations of 0.43 to 0.19 microg/L from day 7 until before the next injection.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],20,240917,DB00007,Leuprolide
,12083977,continuous drug concentrations,"A 3-month depot PLA formulation of leuprorelin acetate 11.25mg ensures a C(max) of around 20 microg/L at 3 hours after subcutaneous injection, and continuous drug concentrations of 0.43 to 0.19 microg/L from day 7 until before the next injection.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],0.43 to 0.19,240918,DB00007,Leuprolide
,21964316,P(app),"Due to the addition of gel formulations comprising 0.5% (m/v) unmodified chitosan/0.5% (m/v) GSH and 0.5% (m/v) chitosan-TGA/0.5% (m/v) GSH, the transport of leuprolide across excised mucosa was improved up to 2.06-fold and 3.79-fold, respectively, in comparison with leuprolide applied in buffer (P(app)=2.87 ± 0.77 × 10⁻⁶ cm/s).",Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21964316/),[cm] / [s],2.87,252533,DB00007,Leuprolide
,21964316,relative bioavailability,"With the oral gel formulation comprising 8 mg of chitosan-TGA, a relative bioavailability (versus s.c. injection) of 4.5% was achieved in contrast to the control displaying a relative bioavailability of 1.2%.",Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21964316/),%,4.5,252534,DB00007,Leuprolide
,21964316,relative bioavailability,"With the oral gel formulation comprising 8 mg of chitosan-TGA, a relative bioavailability (versus s.c. injection) of 4.5% was achieved in contrast to the control displaying a relative bioavailability of 1.2%.",Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21964316/),%,1.2,252535,DB00007,Leuprolide
